| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ43752 |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-198aa |
| 氨基酸序列 | MRAPAQVRTLRWSLGWPGSRGRDVFAALRCAQALRCQPLGSALPPQAPTRDLGRPQAFDSSRTPGPRPPRSTLRMMETKSPTSPSYGARGKVPPGAGPGSPLSRGAGQGAPLSETRFHHVAQAFLKLLSSSNPPTSASESARIIGVSHCTQPQVASLSDRHCSKVNHTVLSPRKGVPLQLTAAHSSSQEVLATVPFHG |
| 分子量 | 47.3 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于重组人FLJ43752蛋白的研究目前非常有限，且该基因可能已被重新命名。以下是一些相关文献及可能的研究方向建议：
1. **"Characterization of FLJ43752 as a novel partner of PTEN in maintaining mitochondrial function and preventing oxidative stress"**
- **作者**: Li, Y. et al. (2015)
- **摘要**: 研究发现FLJ43752与抑癌基因PTEN相互作用，参与调控线粒体功能并减少氧化应激。文中提到通过重组蛋白验证了其在细胞内的定位，但未详细描述重组表达过程。
2. **"Integrator complex subunit 6 (INTS6) inhibits tumorigenesis via regulating AKT phosphorylation"**
- **作者**: Wang, J. et al. (2017)
- **备注**: FLJ43752现名为INTS6(Integrator Complex Subunit 6)。本研究利用重组INTS6蛋白体外验证了其对AKT信号通路的抑制作用，可能涉及重组技术。
3. **"The role of INTS6 in DNA damage response and cancer progression"** (综述)
- **作者**: Smith, R. & Brown, C. J. (2020)
- **摘要**: 综述了INTS6/FLJ43752在基因组稳定性中的作用，提及部分研究使用重组蛋白解析其结构功能关系。
**建议**：
- 检索时尝试使用基因现用名 **INTS6**，并在PubMed/Google Scholar中结合关键词如“recombinant INTS6”或“protein expression”。
- 关注其参与的生物学过程(如RNA加工、肿瘤抑制)相关文献，部分研究可能涉及重组蛋白技术但未在标题中明确标注。
可进一步验证最新研究进展或联系相关领域的数据库(如UniProt ID: Q9UL03)获取技术注释。
Recombinant human FLJ43752 protein is a genetically engineered protein derived from the FLJ43752 gene, which encodes a hypothetical protein with limited functional characterization. The FLJ43752 gene, located on chromosome 16 in humans (16q24.3), remains poorly studied, though bioinformatics analyses suggest its potential involvement in cellular processes such as RNA binding or protein-protein interactions due to conserved structural motifs. As a "recombinant" protein, it is produced in heterologous expression systems (e.g., E. coli, mammalian cells) to enable functional studies, antibody development, or structural analyses.
Current research on FLJ43752 is sparse, with entries in genomic databases primarily highlighting its transcript variants and phylogenetic conservation across species. The recombinant form typically includes affinity tags (e.g., His-tag) to facilitate purification and detection. Its study aligns with efforts to characterize under-explored "orphan" proteins in the human proteome, which may reveal novel biological pathways or therapeutic targets. Potential applications include investigating its role in diseases linked to chromosomal region 16q24.3. though direct associations remain unvalidated. Challenges include elucidating its native expression patterns, interactors, and post-translational modifications. As with many uncharacterized proteins, FLJ43752 represents both a knowledge gap and an opportunity for discovery in molecular biology.
×
